跳至主要内容
临床试验/NCT05192616
NCT05192616进行中(未招募)不适用

Prospective, Multicenter, Non-randomized, Single-arm Observational Study to Evaluate Safety and Effectiveness of iCover Covered Stent for the Treatment of the Aorto-iliac Occlusive Disease

iVascular S.L.U.18 个研究点 分布在 4 个国家目标入组 241 人开始时间: 2022年4月27日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
241
试验地点
18
主要终点
Primary Patency

研究概览

简要总结

The objective of this prospective, multi-center, non-randomized, single-arm observational study is to evaluate the safety and the efficacy of the iCover covered stent over a 24-month follow-up period for the treatment of de novo iliac occlusive lesions, defined by a significant vessel stenosis ≥70%, in patients with symptomatic arteriopathy of the lower limbs (Rutherford class 2 to 5).

详细描述

This is a prospective, single-arm, multinational, and multicenter study conducted to evaluate the safety and efficacy of the iCover covered stent for the treatment of de novo iliac occlusive lesions (common and/or external iliac arteries) in patients with symptomatic lower limb arteriopathy. The primary endpoint of the study is primary patency, defined as the absence of restenosis in the target lesion over a 12-month follow-up period in patients who did not undergo a reintervention on the target lesion. Restenosis is defined as a reduction in the luminal diameter of more than 50%, assessed either by duplex ultrasound (considered as a peak systolic velocity index ≥ 2.4 at the target lesion) or by angio-CT (multiplanar reconstruction). Secondary endpoints include: technical and procedural success rate, freedom from all major adverse events, incidence of procedure- or device-related major local complications at the treated lesion, rate of SAEs, major amputation rate at the target limb, primary sustained clinical improvement (improvement in Rutherford classification), primary and secondary patency rates, TLR and TVR rates, and changes in ABI, the Walking Impairment Questionnaire, and the EQ-5D questionnaire from baseline.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Primary Patency

时间窗: 12 months after index procedure.

The primary patency, defined as the absence of restenosis in the target lesion over the 12-month follow-up period in patients who did not undergo a reintervention on the target lesion.

次要结局

  • Procedural success rate(Day 0.)
  • Rates of Serious Adverse Events (SAEs)(1, 6, 12, 24 months after index procedure.)
  • Major amputation at target limb rate(1, 6, 12, 24 months after index procedure.)
  • Change in Walking Impairment Questionnaire from baseline(1, 6, 12, 24 months post-procedure.)
  • Freedom from All Major Adverse Event (MAEs)(1, 6, 12, 24 months after index procedure.)
  • Target lesion revascularization (TLR) rate(1, 6, 12, 24 months after index procedure.)
  • Technical success rate(Day 0.)
  • Primary sustained clinical improvement(1, 6, 12, 24 months after index procedure.)
  • Incidence of Procedure- or Device- related Major Local Complications(Up to 30 days after index procedure.)
  • Primary patency rates(6 and 24 months after index procedure.)
  • Secondary patency rates(6, 12, 24 months after index procedure.)
  • Target vessel revascularization (TVR) rate(1, 6, 12, 24 months after index procedure.)
  • Change in Ankle-Brachial Index (ABI) from baseline(1, 6, 12, 24 months post-procedure.)
  • Change in quality of life from baseline(1, 6, 12, 24 months post-procedure.)

研究者

发起方
iVascular S.L.U.
申办方类型
Industry
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验